• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

对于 COVID-19 住院患者，最佳的血栓预防策略是什么？当前存在争议。

Which are the optimal thromboprophylaxis strategies for hospitalized patients with COVID-19? current controversies.

机构信息

Department of Internal Medicine, Divisions of Hospital and Adult Clinical Thrombosis Medicine, Texas Tech University Health Sciences Center and Paul L. Foster School of Medicine, El Paso, TX, USA.

Division of Cardiovascular Diseases, Texas Tech University Health Sciences Center and Paul L. Foster School of Medicine, El Paso, TX, USA.

出版信息

Vascular. 2024 Feb;32(1):220-225. doi: 10.1177/17085381221126235. Epub 2022 Sep 8.

DOI:10.1177/17085381221126235
PMID:36076354
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9459371/
Abstract

Novel coronavirus 2019 (COVID-19) represents a significant risk factor for the development of venous thromboembolism (VTE) in hospitalized with both moderate and severe/critical COVID-19. Herein, we present a brief updated review on emerging robust data on diverse thromboprophylaxis strategies used to mitigate VTE complications, as well as a personal point of view of current controversies in regards the use of therapeutic and prophylactic anticoagulation strategies, particularly in the moderately-ill subgroup of patients with COVID-19.

摘要

新型冠状病毒 2019（COVID-19）是住院的中度和重度/危重新冠肺炎患者发生静脉血栓栓塞（VTE）的一个重要危险因素。在此，我们简要更新了有关各种血栓预防策略的最新数据，这些策略用于减轻 VTE 并发症，以及关于治疗和预防抗凝策略使用的当前争议的个人观点，特别是在 COVID-19 中度疾病亚组的患者中。

相似文献

1
Which are the optimal thromboprophylaxis strategies for hospitalized patients with COVID-19? current controversies.对于 COVID-19 住院患者，最佳的血栓预防策略是什么？当前存在争议。
Vascular. 2024 Feb;32(1):220-225. doi: 10.1177/17085381221126235. Epub 2022 Sep 8.
2
Venous thromboembolism in critically ill COVID-19 patients receiving prophylactic or therapeutic anticoagulation: a systematic review and meta-analysis.危重症 COVID-19 患者接受预防性或治疗性抗凝治疗时的静脉血栓栓塞症：系统评价和荟萃分析。
J Thromb Thrombolysis. 2020 Nov;50(4):814-821. doi: 10.1007/s11239-020-02235-z.
3
Thromboprophylaxis in Patients with COVID-19: Systematic Review of National and International Clinical Guidance Reports.COVID-19 患者的血栓预防：国家和国际临床指南报告的系统评价。
Curr Vasc Pharmacol. 2022;20(1):96-110. doi: 10.2174/1570161119666210824160332.
4
Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial.COVID-19 住院高危患者中治疗剂量肝素与标准预防剂量或中剂量肝素预防血栓的疗效和安全性：HEP-COVID 随机临床试验。
JAMA Intern Med. 2021 Dec 1;181(12):1612-1620. doi: 10.1001/jamainternmed.2021.6203.
5
Trends in Venous Thromboembolism Anticoagulation in Patients Hospitalized With COVID-19.COVID-19 住院患者静脉血栓栓塞症抗凝治疗趋势。
JAMA Netw Open. 2021 Jun 1;4(6):e2111788. doi: 10.1001/jamanetworkopen.2021.11788.
6
Pulmonary Embolism Prophylaxis in Patients With COVID-19: An Emerging Issue.COVID-19 患者的肺栓塞预防：一个新出现的问题。
Heart Lung Circ. 2021 Oct;30(10):1435-1441. doi: 10.1016/j.hlc.2021.04.018. Epub 2021 May 12.
7
Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illness.基于共识的临床建议和研究重点，用于因 COVID-19 相关疾病住院的儿童的抗凝血栓预防。
J Thromb Haemost. 2020 Nov;18(11):3099-3105. doi: 10.1111/jth.15073.
8
Anticoagulation for COVID-19 Patients: A Bird's-Eye View.COVID-19 患者的抗凝治疗：鸟瞰。
Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211039288. doi: 10.1177/10760296211039288.
9
Prothrombotic Milieu, Thrombotic Events and Prophylactic Anticoagulation in Hospitalized COVID-19 Positive Patients: A Review.COVID-19 阳性住院患者的促血栓形成环境、血栓形成事件和预防性抗凝治疗：综述。
Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221074353. doi: 10.1177/10760296221074353.
10
Pragmatic Recommendations for the Management of Anticoagulation and Venous Thrombotic Disease for Hospitalized Patients with COVID-19 in Low- and Middle-Income Countries.中低收入国家 COVID-19 住院患者抗凝和静脉血栓疾病管理的实用建议。
Am J Trop Med Hyg. 2021 Jan 11;104(3_Suppl):99-109. doi: 10.4269/ajtmh.20-1305.

引用本文的文献

1
The effect of antibiotic prescription in non-critically ill hospitalized patients with COVID-19: A Japanese inpatient database study.抗生素处方对非重症COVID-19住院患者的影响：一项日本住院患者数据库研究。
PLoS One. 2025 Mar 25;20(3):e0318803. doi: 10.1371/journal.pone.0318803. eCollection 2025.

本文引用的文献

1
"ISTH guidelines for antithrombotic treatment in COVID-19": Reply.“国际血栓与止血学会（ISTH）关于COVID-19抗栓治疗的指南”：回复
J Thromb Haemost. 2022 Nov;20(11):2710-2711. doi: 10.1111/jth.15854.
2
Thromboprophylaxis Strategies for Hospitalized Patients With COVID-19.新冠病毒肺炎住院患者的血栓预防策略
Chest. 2022 Jul;162(1):e69-e70. doi: 10.1016/j.chest.2022.03.038.
3
Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum.COVID-19 大流行期间的血栓栓塞预防和抗凝治疗：抗凝论坛的最新临床指南。
J Thromb Thrombolysis. 2022 Aug;54(2):197-210. doi: 10.1007/s11239-022-02643-3. Epub 2022 May 17.
4
American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients.美国血液学会 COVID-19 患者血栓预防抗凝治疗临床实践指南：2022 年 1 月关于急性重症患者强化抗凝治疗的更新
Blood Adv. 2022 Sep 13;6(17):4915-4923. doi: 10.1182/bloodadvances.2022007561.
5
Thromboprophylaxis in Patients With COVID-19: A Brief Update to the CHEST Guideline and Expert Panel Report.COVID-19 患者的血栓预防：对 CHEST 指南和专家小组报告的简要更新。
Chest. 2022 Jul;162(1):213-225. doi: 10.1016/j.chest.2022.02.006. Epub 2022 Feb 12.
6
Risk assessment of venous thromboembolism and bleeding in COVID-19 patients.新型冠状病毒肺炎患者静脉血栓栓塞症与出血的风险评估。
Clin Respir J. 2022 Mar;16(3):182-189. doi: 10.1111/crj.13467. Epub 2022 Jan 21.
7
COVID-19 and thrombosis: searching for evidence.COVID-19 与血栓：探寻证据。
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):621-627. doi: 10.1182/hematology.2021000298.
8
Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial.治疗性肝素与预防性肝素对中症 COVID-19 住院患者的死亡、机械通气或入住重症监护病房的影响：RAPID 随机临床试验。
BMJ. 2021 Oct 14;375:n2400. doi: 10.1136/bmj.n2400.
9
Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial.COVID-19 住院高危患者中治疗剂量肝素与标准预防剂量或中剂量肝素预防血栓的疗效和安全性：HEP-COVID 随机临床试验。
JAMA Intern Med. 2021 Dec 1;181(12):1612-1620. doi: 10.1001/jamainternmed.2021.6203.
10
American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients.美国血液学会关于 COVID-19 患者血栓预防中抗凝治疗的临床实践指南：2021 年 5 月关于危重症患者中强度抗凝治疗的更新。
Blood Adv. 2021 Oct 26;5(20):3951-3959. doi: 10.1182/bloodadvances.2021005493.